AP1893A - Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof - Google Patents

Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof

Info

Publication number
AP1893A
AP1893A APAP/P/2003/002807A AP2003002807A AP1893A AP 1893 A AP1893 A AP 1893A AP 2003002807 A AP2003002807 A AP 2003002807A AP 1893 A AP1893 A AP 1893A
Authority
AP
ARIPO
Prior art keywords
adenosine
receptor
compounds
compounds specific
receptors
Prior art date
Application number
APAP/P/2003/002807A
Other versions
AP2003002807A0 (en
Inventor
Arlindo L Castelhano
Original Assignee
Osi Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/728,316 external-priority patent/US6680322B2/en
Priority claimed from US09/728,607 external-priority patent/US6664252B2/en
Priority claimed from US09/728,616 external-priority patent/US7160890B2/en
Application filed by Osi Pharm Inc filed Critical Osi Pharm Inc
Publication of AP2003002807A0 publication Critical patent/AP2003002807A0/en
Application granted granted Critical
Publication of AP1893A publication Critical patent/AP1893A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention pertains to compounds which specifically inhibit the adenosine A1, A2A and A3 receptors and the use of the compounds to treat a disease associated with A1, A2A, A3 adenosine receptors in a subjects, comprising administering to the subject a therapeutically effective amount of the compounds.
APAP/P/2003/002807A 2000-12-01 2001-11-30 Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof AP1893A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US09/728,316 US6680322B2 (en) 1999-12-02 2000-12-01 Compounds specific to adenosine A1 receptors and uses thereof
US09/728,607 US6664252B2 (en) 1999-12-02 2000-12-01 4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
US09/728,616 US7160890B2 (en) 1999-12-02 2000-12-01 Compounds specific to adenosine A3 receptor and uses thereof
PCT/US2001/045280 WO2002057267A1 (en) 2000-12-01 2001-11-30 Compounds specific to adenosine a1, a2a, and a3 receptor and uses thereof

Publications (2)

Publication Number Publication Date
AP2003002807A0 AP2003002807A0 (en) 2003-06-30
AP1893A true AP1893A (en) 2008-09-23

Family

ID=27419112

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2003/002807A AP1893A (en) 2000-12-01 2001-11-30 Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof

Country Status (20)

Country Link
EP (1) EP1347980A4 (en)
JP (1) JP4579497B2 (en)
CN (1) CN1263757C (en)
AP (1) AP1893A (en)
AU (1) AU2002248151B2 (en)
BR (1) BR0115847A (en)
CA (1) CA2430577A1 (en)
CZ (1) CZ20031831A3 (en)
EA (1) EA007254B1 (en)
HU (1) HUP0400692A3 (en)
IL (1) IL155962A0 (en)
ME (1) MEP35308A (en)
MX (1) MXPA03004717A (en)
NO (1) NO327207B1 (en)
NZ (1) NZ525885A (en)
OA (1) OA13295A (en)
PL (1) PL363245A1 (en)
WO (1) WO2002057267A1 (en)
YU (1) YU42703A (en)
ZA (1) ZA200303729B (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5090531A (en) * 1990-01-10 1992-02-25 Lord Corporation Electrophoretic fluid differential
EA003604B1 (en) 1998-06-02 2003-06-26 Оси Фармасьютикалз, Инк. Pyrrolo[2,3]pyrimidine compositions and their use
US6680324B2 (en) 2000-12-01 2004-01-20 Osi Pharmaceuticals, Inc. Compounds specific to adenosine A1 receptors and uses thereof
DE10148883A1 (en) * 2001-10-04 2003-04-10 Merck Patent Gmbh New fused bi- or tricyclic pyrimidine derivatives, are phosphodiesterase V inhibitors useful e.g. for treating impotence, cardiovascular disorders, inflammation or tumors
JP2005529062A (en) 2001-11-30 2005-09-29 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Compounds specific for adenosine A1 and A3 receptors and uses thereof
MXPA04005510A (en) * 2001-12-07 2006-02-24 Vertex Pharma Pyrimidine-based compounds useful as gsk-3 inhibitors.
CN1816551A (en) 2001-12-20 2006-08-09 Osi药物公司 Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
AU2002366811B2 (en) 2001-12-20 2009-01-15 Osi Pharmaceuticals, Inc. Pyrimidine A2B selective antagonist compounds, their synthesis and use
US7199119B2 (en) * 2002-10-31 2007-04-03 Amgen Inc. Antiinflammation agents
HUP0203976A3 (en) * 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
UY29177A1 (en) 2004-10-25 2006-05-31 Astex Therapeutics Ltd SUBSTITUTED DERIVATIVES OF PURINA, PURINONA AND DEAZAPURINA, COMPOSITIONS THAT CONTAIN METHODS FOR THEIR PREPARATION AND ITS USES
MY179032A (en) 2004-10-25 2020-10-26 Cancer Research Tech Ltd Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors
ES2344800T3 (en) * 2005-02-18 2010-09-07 Solvay Pharmaceuticals Gmbh PHARMACEUTICAL COMPOSITIONS THAT INCLUDE NEP INHIBITORS, INHIBITORS OF THE ENDOGELINE AND DIURETIC ENDOTELINE PRODUCTION SYSTEM.
EP3421471B1 (en) 2006-04-25 2021-05-26 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
US20070260203A1 (en) * 2006-05-04 2007-11-08 Allergan, Inc. Vasoactive agent intraocular implant
TW200808819A (en) * 2006-06-19 2008-02-16 Solvay Pharm Gmbh Use of adenosine A1 antagonists in radiocontrast media induced nephrophaty
PL2201012T3 (en) 2007-10-11 2014-11-28 Astrazeneca Ab Pyrrolo[2,3-d]pyrimidin derivatives as protein kinase b inhibitors
MX2010007523A (en) 2008-01-11 2010-08-18 Natco Pharma Ltd Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents.
AR070127A1 (en) 2008-01-11 2010-03-17 Novartis Ag PIRROLO - PIRIMIDINAS AND PIRROLO -PIRIDINAS
JP6080837B2 (en) 2011-04-01 2017-02-15 アストラゼネカ アクチボラグ Therapeutic treatment
PL2785349T5 (en) 2011-11-30 2023-01-30 Astrazeneca Ab Combination treatment of cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms
RU2014151004A (en) * 2012-06-07 2016-08-10 Ф. Хоффманн-Ля Рош Аг Pyrrolopyrimidone and pyrrolopyridone TANKYRASE INHIBITORS
NZ754629A (en) 2013-06-21 2021-07-30 Zenith Epigenetics Ltd Novel bicyclic bromodomain inhibitors
EP3010917B1 (en) * 2013-06-21 2018-01-31 Zenith Epigenetics Ltd. Novel substituted bicyclic compounds as bromodomain inhibitors
CN105593224B (en) 2013-07-31 2021-05-25 恒元生物医药科技(苏州)有限公司 Novel quinazolinones as bromodomain inhibitors
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
WO2016087942A1 (en) 2014-12-01 2016-06-09 Zenith Epigenetics Corp. Substituted pyridines as bromodomain inhibitors
HK1245248B (en) 2014-12-11 2020-05-15 恒翼生物医药(上海)股份有限公司 Substituted heterocycles as bromodomain inhibitors
CN107406438B (en) 2014-12-17 2021-05-14 恒翼生物医药科技(上海)有限公司 Inhibitors of bromodomains
MX380276B (en) * 2015-01-20 2025-03-12 Wuxy Fortune Pharmaceutical Co Ltd JAK INHIBITOR.
CN107531695B (en) 2015-04-29 2020-03-27 无锡福祈制药有限公司 JAK inhibitors
US10174056B2 (en) 2015-05-29 2019-01-08 Wuxi Fortune Pharmaceutical Co., Ltd Substituted pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
CN105771672B (en) * 2016-04-18 2018-03-02 天津工业大学 A kind of antipollution antibiotic aromatic polyamide reverse osmosis composite film and preparation method
EP3594216B1 (en) * 2017-03-07 2022-04-06 Guangzhou Maxinovel Pharmaceuticals Co., Ltd. Aminopyrimidine five-membered heterocyclic compound, and intermediate, preparation method, pharmaceutical composition and application thereof
CN108017584B (en) * 2017-06-20 2021-03-23 南开大学 A3Small molecule antagonists of adenosine receptors
CN118834214A (en) * 2018-06-04 2024-10-25 爱克思科技有限公司 As adenosine receptor antagonists pyrazolopyrimidine compounds of (2)
CN110128316B (en) * 2019-05-22 2021-08-31 北京大学深圳研究生院 The preparation method of 5-substituted β-proline and its derivatives
CN110272373B (en) * 2019-07-02 2022-07-29 天津国际生物医药联合研究院 Selective adenosine A 1 Receptor antagonists and uses thereof
CN114085178A (en) * 2021-12-29 2022-02-25 苏州楚凯药业有限公司 Preparation method of 4-methyl-1-propyl-2-amino-1H-pyrrole-3-nitrile

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062518A1 (en) * 1998-06-02 1999-12-09 Osi Pharmaceuticals, Inc. PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE
WO2001039777A1 (en) * 1999-12-02 2001-06-07 Osi Pharmaceuticals, Inc. Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
WO2003048120A2 (en) * 2001-11-30 2003-06-12 Osi Pharmaceuticals, Inc. 2-aryl pyrrologpyrimidines for a1 and a3 receptors

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994013676A1 (en) * 1992-12-17 1994-06-23 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
US5780450A (en) * 1995-11-21 1998-07-14 Alcon Laboratories, Inc. Use of adenosine uptake inhibitors for treating retinal or optic nerve head damage

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999062518A1 (en) * 1998-06-02 1999-12-09 Osi Pharmaceuticals, Inc. PYRROLO[2,3d]PYRIMIDINE COMPOSITIONS AND THEIR USE
WO2001039777A1 (en) * 1999-12-02 2001-06-07 Osi Pharmaceuticals, Inc. Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
WO2003048120A2 (en) * 2001-11-30 2003-06-12 Osi Pharmaceuticals, Inc. 2-aryl pyrrologpyrimidines for a1 and a3 receptors

Also Published As

Publication number Publication date
CN1489590A (en) 2004-04-14
JP4579497B2 (en) 2010-11-10
AU2002248151B2 (en) 2008-02-21
CN1263757C (en) 2006-07-12
EA007254B1 (en) 2006-08-25
PL363245A1 (en) 2004-11-15
EA200300628A1 (en) 2003-12-25
NO327207B1 (en) 2009-05-11
MXPA03004717A (en) 2004-06-30
NO20032482L (en) 2003-07-28
HUP0400692A3 (en) 2007-09-28
EP1347980A1 (en) 2003-10-01
WO2002057267A1 (en) 2002-07-25
OA13295A (en) 2007-04-13
JP2004517896A (en) 2004-06-17
EP1347980A4 (en) 2005-02-09
MEP35308A (en) 2011-02-10
NZ525885A (en) 2005-01-28
HUP0400692A2 (en) 2004-07-28
BR0115847A (en) 2004-02-25
YU42703A (en) 2006-03-03
ZA200303729B (en) 2004-05-14
AP2003002807A0 (en) 2003-06-30
CZ20031831A3 (en) 2004-05-12
IL155962A0 (en) 2003-12-23
CA2430577A1 (en) 2002-07-25
NO20032482D0 (en) 2003-06-02

Similar Documents

Publication Publication Date Title
AP1893A (en) Compounds specific to adenosine A1, A2A and A3 receptor and uses thereof
WO2001039777A8 (en) Compounds specific to adenosine a1 a2a, and a3 receptors and uses thereof
WO2003048120A3 (en) 2-aryl pyrrologpyrimidines for a1 and a3 receptors
NZ522326A (en) Adenosine A2A receptor antagonists
AP2003002911A0 (en) An adenosine A2A receptor agonist and an anticholinergic agent in combination for treating obstructive airways diseases.
WO2002043652A3 (en) Anti-proliferative drugs
PT1194049E (en) CLOTHING PACK WITH RESPIRATORY CAPACITY, TO BE DRESSED WITH THE INTUITE TO IMPROVE HUMAN BODY COMFORT
BR0115067A (en) Gnrh Analogs for Urinary Incontinence Treatment
MXPA03009185A (en) Adenosine a2a receptor antagonists combined with neurotrophic activity compounds in the treatment of parkinson s disease.
BR0309544A (en) Pharmaceutical preparation containing oxycodone and naloxone
MXPA02000282A (en) Personal care compositions.
MXPA02010801A (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites.
PL1656372T3 (en) 2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
GEP20094798B (en) (s,s)-reboxetine for treating chronic pain
BR0009480A (en) Polyurethane solutions with alkoxysilane structure units
AR023966A1 (en) A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF PARKINSON'S DISEASE AND THE CONCOMITING SYMPTOMS OF THE SAME, AND THE USE OF A DUAL ADENOSINE A1 A2A RECEIVER UNANTAGONIST TO PREPARE SUCH COMPOSITION
NO996583D0 (en) Absorbent disposable items, with improved adaptation to body anatomy
EE05174B1 (en) Use of a Chemokine Mutant for the Preparation of a Pharmaceutical Composition for the Treatment of Multiple Sclerosis and Other Mine Loss Diseases
IL156069A0 (en) Use of a substance which binds to sarp-1 receptor or influences the activity of endogenous sarp-1 in scleroderma
EE200100689A (en) Use of IL6RIL6 Chimera for the preparation of a medicament for the treatment of neurological diseases, and pharmaceutical composition
TWI256388B (en) Pharmaceutical combination
BR0115413A (en) Premature Ejaculation Treatment
WO1999038500A3 (en) The human calcium-sensing receptor in the detection and treatment of cancer
AU2003264195A8 (en) Use of guanosine or inosine as anti-apoptotic agents in the treatment of i. a. neurodegenerative diseases or injuries at the nervous system
MX2007004506A (en) Antiviral oligonucleotides.